Renaissance Technologies LLC Has $9.15 Million Position in Rigel Pharmaceuticals, Inc. $RIGL

Posted by Francis Steltz on Aug 3rd, 2026

Renaissance Technologies LLC lessened its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL – Free Report) by 37.2% in the first quarter, Holdings Channel reports. The institutional investor owned 338,441 shares of the biotechnology company’s stock after selling 200,568 shares during the period. Renaissance Technologies LLC’s holdings in Rigel Pharmaceuticals were worth $9,151,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in RIGL. AQR Capital Management LLC bought a new stake in Rigel Pharmaceuticals during the 1st quarter worth approximately $191,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Rigel Pharmaceuticals by 14.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,366 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 1,464 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Rigel Pharmaceuticals by 130.7% during the second quarter. Legal & General Group Plc now owns 4,310 shares of the biotechnology company’s stock valued at $81,000 after acquiring an additional 2,442 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Rigel Pharmaceuticals by 2.1% during the second quarter. Rhumbline Advisers now owns 27,065 shares of the biotechnology company’s stock worth $507,000 after purchasing an additional 555 shares during the period. Finally, American Century Companies Inc. acquired a new position in shares of Rigel Pharmaceuticals during the second quarter worth $317,000. 66.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Kamil Ali-Jackson sold 2,500 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $35.00, for a total value of $87,500.00. Following the transaction, the director owned 10,125 shares in the company, valued at $354,375. The trade was a 19.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.47% of the stock is owned by corporate insiders.

Rigel Pharmaceuticals Price Performance

Rigel Pharmaceuticals stock opened at $36.81 on Monday. The firm has a market cap of $681.06 million, a price-to-earnings ratio of 1.97 and a beta of 1.14. Rigel Pharmaceuticals, Inc. has a 52-week low of $20.28 and a 52-week high of $52.24. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.48 and a current ratio of 2.62. The firm has a 50 day moving average price of $35.92 and a two-hundred day moving average price of $32.95.

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.44 EPS for the quarter, missing analysts’ consensus estimates of $0.80 by ($0.36). Rigel Pharmaceuticals had a net margin of 121.50% and a return on equity of 47.99%. The firm had revenue of $58.82 million during the quarter, compared to the consensus estimate of $62.40 million. Equities analysts predict that Rigel Pharmaceuticals, Inc. will post 3.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on RIGL. Weiss Ratings reissued a “hold (c+)” rating on shares of Rigel Pharmaceuticals in a research note on Friday, July 17th. Zacks Research lowered Rigel Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Thursday, May 7th. Citigroup reaffirmed a “buy” rating and set a $81.00 target price (up from $69.00) on shares of Rigel Pharmaceuticals in a report on Wednesday, May 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $57.00 price target on shares of Rigel Pharmaceuticals in a research report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $54.50.

Get Our Latest Stock Analysis on Rigel Pharmaceuticals

About Rigel Pharmaceuticals

(Free Report)

Rigel Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. Founded in 2003, Rigel focuses on the discovery, development and commercialization of novel small molecule therapeutics targeting immune, hematologic and oncologic diseases. Leveraging a proprietary chemistry platform and expertise in signal transduction pathways, the company aims to address significant unmet medical needs in both rare and common disorders.

Rigel’s lead product, fostamatinib (commercially known as Tavalisse®), is an oral spleen tyrosine kinase (SYK) inhibitor approved in the United States for the treatment of adult patients with chronic immune thrombocytopenia (ITP).